SparingVision raises €75m for eye disease gene therapies
pharmaphorum
SEPTEMBER 14, 2022
The French biotech said the cash injection – which follows a €45 million Series A in 2020 – will also help it bring forward the first development candidate in a collaboration signed with gene-editing specialist Intellia Therapeutics last year, currently in the early-discovery stage.
52 
Let's personalize your content